Physician
Trenkle, Geoffrey
Trenkle, Geoffrey was paid $6.47M by Medicaid between Jan 2018 and Dec 2024, across 54 billing codes. Its largest line is 99204, doctor's office visit, new patient (more involved) — 26% of everything it billed.
33Billing provider infoTRENKLE, GEOFFREY
LOS ANGELES, CA 90033
LOS ANGELES, CA 90033
33aNPI1003044876assigned 06/30/2009
33bProvider typeFacial Plastic Surgery Physician
28Total paid$6.47M
24GClaims93,847
24DCodes billed54
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Facial Plastic Surgery Physician providers in California
Rank by total paid#1 of 13
Median peer was paid$33K
This provider vs. median197×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,141 | $155K | |
| 2019 | 3,397 | $362K | |
| 2020 | 6,419 | $575K | |
| 2021 | 8,450 | $617K | |
| 2022 | 18,836 | $1.08M | |
| 2023 | 20,428 | $1.64M | |
| 2024incomplete | 34,176 | $2.05M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 26% | 13,749 | 13,728 | $1.68M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 18% | 15,035 | 13,836 | $1.17M |
| 31231 | 12% | 5,049 | 4,972 | $781K | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 11% | 10,724 | 10,017 | $719K |
| 31575 | 5.4% | 3,517 | 3,484 | $350K | |
| 31237 | 2.0% | 601 | 526 | $126K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | 1.9% | 1,099 | 1,045 | $121K |
| 92557 | 1.8% | 4,196 | 4,184 | $114K | |
| 95024 | 1.7% | 542 | 541 | $110K | |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | 1.5% | 594 | 570 | $99K |
| 99205 | Prolong outpt/office vis | 1.5% | 652 | 651 | $95K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.4% | 882 | 849 | $93K |
42 more codes
| 70486 | 1.2% | 1,013 | $78K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 1.1% | 2,138 | $73K |
| 31579 | 1.1% | 554 | $72K | |
| 92550 | 1.1% | 4,192 | $70K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.0% | 3,112 | $66K |
| 92612 | <1% | 371 | $50K | |
| 92587 | <1% | 2,824 | $43K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 680 | $42K |
| 92524 | <1% | 548 | $38K | |
| 95117 | <1% | 4,232 | $36K | |
| 99442 | <1% | 631 | $35K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,253 | $31K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 2,387 | $30K |
| 92540 | <1% | 411 | $28K | |
| 69210 | <1% | 778 | $26K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,087 | $25K |
| 97162 | <1% | 405 | $24K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 407 | $23K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 557 | $22K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,272 | $18K |
| 70480 | <1% | 208 | $17K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 976 | $17K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 713 | $15K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,047 | $15K |
| 95992 | <1% | 540 | $14K | |
| 30520 | <1% | 26 | $14K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 879 | $13K |
| 92610 | <1% | 263 | $13K | |
| 92537 | <1% | 411 | $12K | |
| 95800 | <1% | 190 | $11K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 554 | $11K |
| 92526 | <1% | 186 | $8K | |
| 30140 | <1% | 40 | $8K | |
| 97035 | <1% | 347 | $3K | |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | <1% | 598 | $2K |
| 99441 | <1% | 64 | $2K | |
| 92520 | <1% | 12 | $998.89 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 66 | $903.98 |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 14 | $534.86 |
| 99422 | <1% | 19 | $390.18 | |
| 92567 | <1% | 12 | $182.31 | |
| 92591 | <1% | 190 | $75.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.